An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
Titel:
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
Auteur:
Murakami, H. Kurata, T. Onozawa, Y. Watanabe, J. Ono, A. Takahashi, T. Yamamoto, N. Fujisaka, Y. Kiyota, H. Hayashi, H. Tanaka, K. Nakagawa, K. Kuroda, S.